- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Antiviral Treatment Promising for preserving residual insulin production in children with new-onset T1D
In a recent study antiviral treatment has demonstrated its potential to preserve insulin production in children and adolescents with newly diagnosed type 1 diabetes (T1D). A phase 2 clinical trial, known as the Diabetes Virus Detection (DiViD) Intervention, has yielded promising results, paving the way for further exploration of antiviral strategies in T1D prevention and treatment. This study was published in Nature Medicine by Krogvold L and colleagues.
The DiViD Intervention trial, a phase 2 effort, was designed as a placebo-controlled, randomized, parallel-group, double-blind study. The study enrolled 96 children and adolescents aged 6 to 15 years, all diagnosed with new-onset T1D. These participants were divided into two groups, with one group receiving antiviral treatment consisting of pleconaril and ribavirin (47 participants) and the other group receiving a placebo (49 participants). The treatment duration spanned 6 months, with the primary goal of preserving β cell function.
The primary endpoint of the study was the mean stimulated C-peptide area under the curve (AUC) at 12 months from the initiation of treatment (which began less than 3 weeks after diagnosis). The analysis employed a mixed linear model using longitudinal log-transformed serum C-peptide AUCs at baseline, 3 months, 6 months, and 1 year.
The primary endpoint was met successfully, as the pleconaril and ribavirin treatment group exhibited a significantly higher serum C-peptide AUC at 12 months compared to the placebo group. The average marginal effect was calculated at 0.057 in the linear mixed model, with a 95% confidence interval ranging from 0.004 to 0.11 and a P-value of 0.037. Additionally, the treatment was well tolerated, indicating a favourable safety profile.
These findings represent a significant step forward in the fight against T1D, particularly in children and adolescents. The potential of antiviral treatment to preserve residual insulin production offers hope for improved diabetes management and quality of life for those affected by this condition.
This success in the DiViD Intervention trial underscores the need for further exploration and evaluation of antiviral strategies in both preventing and treating T1D. The study's results have opened a promising avenue for research and development in the quest to combat this chronic autoimmune disease.
Reference:
Krogvold, L., Mynarek, I. M., Ponzi, E., Mørk, F. B., Hessel, T. W., Roald, T., Lindblom, N., Westman, J., Barker, P., Hyöty, H., Ludvigsson, J., Hanssen, K. F., Johannesen, J., & Dahl-Jørgensen, K. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nature Medicine,2023:1–7. https://doi.org/10.1038/s41591-023-02576-1
Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751